OncoZenge AB (publ) reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was SEK 46.65 million compared to SEK 3.89 million a year ago. Basic loss per share from continuing operations was SEK 3.98 compared to SEK 0.33 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.49 SEK | -2.92% | -5.93% | +12.94% |
05-21 | OncoZenge AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-08 | Oncozenge AB Appoints Paolo Bossi as Member of the Advisory Board | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+12.94% | 3.92M | |
+38.69% | 723B | |
+34.28% | 595B | |
-4.49% | 369B | |
+20.24% | 332B | |
+2.12% | 282B | |
+17.02% | 244B | |
+9.31% | 208B | |
-5.07% | 205B | |
-0.35% | 168B |
- Stock Market
- Equities
- ONCOZ Stock
- News OncoZenge AB
- OncoZenge AB Reports Earnings Results for the Full Year Ended December 31, 2022